NASDAQ$ALXO
ALX Oncology Holdings Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
ALX Oncology's financial results for the second quarter of 2022 were reported, along with clinical development and operational highlights.
ALX Oncology reported a net loss of $32.9 million for the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $324.2 million as of June 30, 2022, which is expected to fund operations through the fourth quarter of 2024. The FDA granted Fast Track designation to evorpacept for HNSCC and Orphan Drug Designation for AML.
- FDA granted Fast Track designation to evorpacept for first-line treatment of HNSCC.
- FDA granted Orphan Drug Designation to evorpacept for the treatment of patients with AML.
- ASPEN-07, a Phase 1 trial of evorpacept for the treatment of patients with urothelial carcinoma, is anticipated to start in Q4 2022.
- Patient enrollment continues for ASPEN-03 and ASPEN-04, Phase 2 studies for advanced HNSCC, with results expected by mid-2024.
Headline financials
Revenue & EPS history
ALX Oncology · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.7%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+26.0%
Q4 2024
Best reaction
-21.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -10.2% | -6.8% | -13.2% | |
| Q3 2025 | +15.5% | +8.5% | +20.3% | |
| Q2 2025 | +7.4% | +57.9% | +72.4% | |
| Q1 2025 | -8.2% | -0.2% | +25.9% | |
| Q4 2024 | +26.0% | -6.4% | -50.4% | |
| Q3 2024 | -5.2% | -12.4% | +5.9% | |
| Q1 2024 | -2.4% | -8.7% | -45.8% | |
| Q4 2023 | +3.0% | -16.2% | -17.2% | |
| Q3 2023 | +13.2% | +21.8% | +70.5% | |
| Q2 2023 | +1.4% | -2.6% | -1.4% | |
| Q1 2023 | +0.6% | -7.0% | +23.3% | |
| Q4 2022 | -13.6% | -15.9% | -28.7% | |
| Q3 2022 | -1.8% | +1.1% | -14.2% | |
| Q2 2022 | +2.6% | +26.6% | +5.6% | |
| Q1 2022 | -6.8% | -8.1% | -24.1% | |
| Q4 2021 | +7.7% | -1.3% | +2.7% | |
| Q3 2021 | +8.8% | +6.3% | -26.4% | |
| Q2 2021 | +0.6% | +2.1% | +16.6% | |
| Q1 2021 | -1.1% | -1.6% | +7.3% | |
| Q4 2020 | -21.9% | -19.4% | -24.8% | |
| Q3 2020 | +4.2% | +34.6% | +65.1% | |
| Q2 2020 | +2.0% | -3.8% | -10.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro